PF-4708671

Licensed and Manufactured by Pfizer Catalog No.S2163

Molecular Weight(MW): 390.41

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with K_i/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.

5 Customer Reviews

(F) EGR-2 and GFI-1 abundance (n = 5).

Front Immunol, 2017, 7:685. PF-4708671 purchased from Selleck.

Tumor sections were examined for DNA fragmentation (TUNEL) or stained with Ki-76 antibody. The representative images are shown. The brown color indicates the positively stained cells; scale bar, 50 mm.

Mol Cancer Ther, 2015, 14(3): 799-809. PF-4708671 purchased from Selleck.
C. Cell lines were treated with the indicated compounds for 24h. ABC cells are colored in red. GCB are colored in blue. Intermediate cells are colored in gray.

Oncotarget, 2016, 7(8):9163-74. PF-4708671 purchased from Selleck.

Effect of PF-4708671 on lipid accumulation and expression of lipogenic genes in HepG2 cells. Cells were exposed to 6 μM PF-4708671, 144 μM PA (sodium palmitate), or 14 nM RAPA (Rapamycin) for different periods of time. (b) The intracellular lipid content in each group was quantified. (c) Detection of TG levels.

Nutr Metab (Lond), 2018, 15:31. PF-4708671 purchased from Selleck.
After treated with PF-4708671 (PF, 10 uM) and 4EGI-1 (50 uM) for 48 h, GRP78 and ATF4 in QBC939, RBE and HCCC-9810 cells were analyzed using western blot.

PLoS One 2014 9(2), e90388. PF-4708671 purchased from Selleck.

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description

Targets

p70 S6K1 ^[1]
(Cell-free assay)

160 nM

In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BHT-101	M4PxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwOEKwNlQh\|ryP	NXviVpRMW0GQR1XS
UACC-893	NGSwSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTVwMUm4PFYh\|ryP	NHLzc4RUSU6JRWK=
A427	Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\yTWM2OD13LkeyOVY4KM7:TR?=	Mkj0V2FPT0WU
OCUB-M	NX61eVVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTZwNk[xNFIh\|ryP	MX\TRW5ITVJ?
SW684	Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTdwNUKyOlgh\|ryP	MlHwV2FPT0WU
SK-LMS-1	NHLzUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLTTWM2OD17LkCxN\|AzKM7:TR?=	NWHnZWdPW0GQR1XS
CP50-MEL-B	M4fKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\uRotLUUN3ME25MlMxPDF7IN88US=>	M3y3U3NCVkeHUh?=
NCI-H1651	NEnZWpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3EW\|ZOUUN3ME2xNE4xOjd4IN88US=>	M2TQOnNCVkeHUh?=
ABC-1	M2DoTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7FTWM2OD1zMD6xNFM4KM7:TR?=	MVnTRW5ITVJ?
OE19	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;VTWM2OD1zMD6xO\|M{KM7:TR?=	NIHuWFlUSU6JRWK=
DSH1	MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHWTWM2OD1zMD64PFc6KM7:TR?=	MV7TRW5ITVJ?
SW13	M3T6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\seWlEPTB;MUGuPVMyQSEQvF2=	MXPTRW5ITVJ?
MDA-MB-453	NUPGS2xiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mne3TWM2OD1zMj6xOlA{KM7:TR?=	NWXCeWdMW0GQR1XS
647-V	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXv4N4k5UUN3ME2xNk4{PTh{IN88US=>	MlTEV2FPT0WU
NCI-H2342	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTUTFZDUUN3ME2xNk4{QTl3IN88US=>	MmHMV2FPT0WU
LB2241-RCC	M3nYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILQTI9KSzVyPUGyMlU4PzlizszN	Mlm4V2FPT0WU
UACC-257	NWDWVXM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmT2TWM2OD1zMz60OFU{KM7:TR?=	M{XaR3NCVkeHUh?=
NCI-H661	MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnG0TWM2OD1zMz62OFQ6KM7:TR?=	NF;SfXhUSU6JRWK=
FADU	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3P1bWlEPTB;MUOuOlk6OiEQvF2=	MVnTRW5ITVJ?
A2780	NXHyUpllT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHobY9PUUN3ME2xN{45ODRzIN88US=>	MUfTRW5ITVJ?
NCI-H1793	NHPhUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUi2VmlVUUN3ME2xOE41ODh3IN88US=>	NHO0XGhUSU6JRWK=
TE-8	NUPl[5JDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLvPFRnUUN3ME2xOU4{PDZ3IN88US=>	M4XiZXNCVkeHUh?=
HGC-27	NHHOVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\hUoh5UUN3ME2xOk4yPjR2IN88US=>	M1THcnNCVkeHUh?=
MMAC-SF	NIT0bJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLiTWM2OD1zNz6zO\|I4KM7:TR?=	NIDuWlJUSU6JRWK=
Calu-6	MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Tw[2lEPTB;MUiuNVUyOyEQvF2=	MljPV2FPT0WU
HUTU-80	NXfHUnNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXjTWM2OD1zOD6zPVU6KM7:TR?=	MVPTRW5ITVJ?
SAS	MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\SWWlEPTB;MUiuOlQ2PSEQvF2=	NHXxN\|ZUSU6JRWK=
IST-MES1	NVXSZWxTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnTfHJKSzVyPUG4MlY2ODhizszN	Mk\FV2FPT0WU
C3A	NH7xWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HFXGlEPTB;MUiuO\|kyQSEQvF2=	NGPNe5FUSU6JRWK=
ES3	NFO2boRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrKbnpKSzVyPUG4Mlg{PjRizszN	MlnJV2FPT0WU
HSC-2	MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLB[lZKSzVyPUG5MlY2PDFizszN	NUO4b49[W0GQR1XS
T47D	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTJyLkG0PFUh\|ryP	NVPHNFRMW0GQR1XS
EW-7	NWX2em1qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTJyLki1PFgh\|ryP	MnXmV2FPT0WU
LN-405	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTsTWM2OD1{MD64PVY2KM7:TR?=	M4DHbXNCVkeHUh?=
U031	NWfXXmlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnlRXhKSzVyPUKxMlQ5ODJizszN	NUfhVm11W0GQR1XS
A549	NGK0OYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorVTWM2OD1{MT64OFkyKM7:TR?=	MUTTRW5ITVJ?
RMG-I	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTJ{LkK2Olgh\|ryP	M2TJZXNCVkeHUh?=
BT-474	NGHqUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXBPJlKSzVyPUKyMlY2PTFizszN	MlrIV2FPT0WU
NB69	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfr[ohUUUN3ME2yN{4yPTJizszN	NFXrVXNUSU6JRWK=
NB7	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTJ2LkG4PEDPxE1?	NH7n[W9USU6JRWK=
HCC1569	M1fsTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mni5TWM2OD1{ND62NVI2KM7:TR?=	MkPwV2FPT0WU
MEL-JUSO	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTJ2Lk[5NFgh\|ryP	M4LVOHNCVkeHUh?=
MDA-MB-175-VII	MmfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;JUXRsUUN3ME2yOU4zPTF5IN88US=>	NXHK[lRRW0GQR1XS
HCC1419	NGTDfY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvZPJZKSzVyPUK1MlYxODNizszN	NHj6Z5RUSU6JRWK=
Ca9-22	Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPpOHJKSzVyPUK1MlY1OzJizszN	Mn3hV2FPT0WU
KGN	M{DaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnGTWM2OD1{NT63OVQ4KM7:TR?=	MW\TRW5ITVJ?
LB373-MEL-D	MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGi5dHRKSzVyPUK2MlE6OzhizszN	MUfTRW5ITVJ?
NCI-H1755	NY\mbGxYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYflNIxbUUN3ME2yOk45QDRzIN88US=>	NETncGJUSU6JRWK=
D-423MG	NV\GUWNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTJ5LkC3NVUh\|ryP	M2TJcnNCVkeHUh?=
DK-MG	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXpbZR2UUN3ME2yPE44QDR4IN88US=>	MYfTRW5ITVJ?
NCI-H1623	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17mcGlEPTB;MkiuPFM1OiEQvF2=	MXXTRW5ITVJ?
KU-19-19	MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3QZphPUUN3ME2yPE46QTVizszN	NXfNUmhFW0GQR1XS
C-33-A	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LFUmlEPTB;MkmuNlE6QCEQvF2=	MV7TRW5ITVJ?
SCC-4	NH;5ZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7FdJBKSzVyPUOwMlM{PTRizszN	NUTqcphiW0GQR1XS
MG-63	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTNyLkW5PVQh\|ryP	MUDTRW5ITVJ?
LNCaP-Clone-FGC	NXTaWpJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVS3dWhuUUN3ME2zNU41QTJzIN88US=>	MYHTRW5ITVJ?
CAPAN-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nMN2lEPTB;M{GuOVI5PiEQvF2=	NVfjclNIW0GQR1XS
GI-ME-N	MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TNNmlEPTB;M{GuOVM2OyEQvF2=	M2fJUXNCVkeHUh?=
RERF-LC-MS	NGX4PFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\1ZlFKSzVyPUOyMlY4PDdizszN	NGP3cGVUSU6JRWK=
KLE	NUm3WFB7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTN\|LkSzN\|Qh\|ryP	MXHTRW5ITVJ?
KNS-81-FD	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\IPI5KSzVyPUOzMlUxODhizszN	MYDTRW5ITVJ?
DOK	M37tWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVn2doo{UUN3ME2zOE43PjF{IN88US=>	M1TPXXNCVkeHUh?=
ACHN	MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfITWM2OD1\|NT6xOVg5KM7:TR?=	NUj1eoxsW0GQR1XS
KYSE-520	NG\uVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfKTWM2OD1\|NT6yN\|YyKM7:TR?=	M1L0XHNCVkeHUh?=
SBC-5	M2H6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfEbos{UUN3ME2zOU42OTF4IN88US=>	Mln0V2FPT0WU
NCI-H28	NILLTYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXhTWM2OD1\|NT62Olk2KM7:TR?=	NYKyUVduW0GQR1XS
ES7	NFfkfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\yTWM2OD1\|Nj6yNlQ6KM7:TR?=	MnLVV2FPT0WU
A172	NV2zSphnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XMWWlEPTB;M{[uOFE5PyEQvF2=	MYHTRW5ITVJ?
UM-UC-3	NUHQd4trT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmG1TWM2OD1\|Nz64O\|Q3KM7:TR?=	MmrrV2FPT0WU
LXF-289	MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTN6LkCwOFch\|ryP	M3H1cXNCVkeHUh?=
KP-4	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTN6LkS3N\|kh\|ryP	Ml:0V2FPT0WU
TE-1	NWDRXYUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjYUIxiUUN3ME2zPU43PTh7IN88US=>	MV;TRW5ITVJ?
G-402	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4KwRmlEPTB;NECuNFYyKM7:TR?=	NFK0bXBUSU6JRWK=
786-0	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HjO2lEPTB;NECuPVA6PiEQvF2=	NYnPUJM6W0GQR1XS
K5	NFzLT3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTRzLkO2PFYh\|ryP	MU\TRW5ITVJ?
SK-N-DZ	MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPsTWM2OD12MT6zPFI{KM7:TR?=	NVTNe3F{W0GQR1XS
OVCAR-4	M1Pyfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPXemUzUUN3ME20NU44PTZ6IN88US=>	MUXTRW5ITVJ?
T84	NUGzdVN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33VZ2lEPTB;NEKuNVI3OyEQvF2=	NGXDR\|BUSU6JRWK=
GCIY	MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTR\|LkC4NFMh\|ryP	NEXWU\|hUSU6JRWK=
BB49-HNC	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTyTWM2OD12Mz6zN\|Q5KM7:TR?=	MofxV2FPT0WU
SNU-C2B	NY\hNINxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HqNWlEPTB;NEOuOlQ{PiEQvF2=	NYTXOZE4W0GQR1XS
TE-6	M1naeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTtTWM2OD12Mz64PFk1KM7:TR?=	NVLvT5R7W0GQR1XS
23132-87	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXZeY44UUN3ME20OE4zQTd6IN88US=>	M4L3bHNCVkeHUh?=
DMS-53	MorES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjybnVKSzVyPUS0MlM{QDRizszN	MlfNV2FPT0WU
ONS-76	NF6z[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPRe4UyUUN3ME20OE44PjZzIN88US=>	MkTFV2FPT0WU
DMS-273	Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fpR2lEPTB;NESuPVQ{KM7:TR?=	MlXLV2FPT0WU
COLO-824	MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTR3Lki3O\|Uh\|ryP	M{Ht[XNCVkeHUh?=
DMS-114	M4LsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3G[pVSUUN3ME20OU45QTJ5IN88US=>	NYOwWHlDW0GQR1XS
YKG-1	NWjnWXdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGezS\|NKSzVyPUS2MlA{PTVizszN	M3rMeHNCVkeHUh?=
RH-18	MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfiOGRKSzVyPUS2MlM4OzNizszN	MmjDV2FPT0WU
NCI-H1355	M3Pi[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfvSmpKSzVyPUS2MlYyQCEQvF2=	NF\KdmJUSU6JRWK=
NCI-H2170	NU\QW5k1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTR5Lke1PFQh\|ryP	M{XxZXNCVkeHUh?=
OC-314	MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\XT2g6UUN3ME20O{45PDd6IN88US=>	MYDTRW5ITVJ?
NCI-H2030	MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPk[lFoUUN3ME20O{45QTB4IN88US=>	Ml\tV2FPT0WU
22RV1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7UTWM2OD12Nz65NFE2KM7:TR?=	NEHQc\|ZUSU6JRWK=
G-401	NUHPbmo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;PeWlEPTB;NEiuOFQyPSEQvF2=	M3XmRnNCVkeHUh?=
YAPC	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTR7LkiwO\|Mh\|ryP	M3HFNnNCVkeHUh?=
SW1573	MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTVyLkK0N\|Uh\|ryP	MULTRW5ITVJ?
COLO-792	NYrzVIRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnKwTWM2OD13MD62NlM4KM7:TR?=	M{jzTHNCVkeHUh?=
KNS-62	MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXUZmtOUUN3ME21NE44PTB6IN88US=>	M{W1PHNCVkeHUh?=
NB5	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LINGlEPTB;NUGuOFUxQSEQvF2=	NX\WWJc{W0GQR1XS
CP66-MEL	NGD2bYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknMTWM2OD13MT62OFA5KM7:TR?=	NVS3PVB{W0GQR1XS
CaR-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTV{LkC2NFYh\|ryP	MX;TRW5ITVJ?
CAL-54	M12xNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTV{LkGxNFIh\|ryP	NET1[5dUSU6JRWK=
8305C	M{TjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLHTWM2OD13Mj6zNVUh\|ryP	MmOxV2FPT0WU
Calu-3	MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LPZ2lEPTB;NUKuN\|c{OyEQvF2=	MkDDV2FPT0WU
AU565	M1XDeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknuTWM2OD13Mj61OVA6KM7:TR?=	Ml;rV2FPT0WU
CW-2	M3SwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTV{Lki2OVQh\|ryP	NXS1VI81W0GQR1XS
BEN	NED0PJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULac212UUN3ME21N{44QDZ{IN88US=>	NWH5cW1xW0GQR1XS
NCI-H1975	M4XlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmi1TWM2OD13Mz64PVY3KM7:TR?=	MnrOV2FPT0WU
HCT-116	MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUftfG94UUN3ME21OE4xOzJ5IN88US=>	NYfQNWpVW0GQR1XS
SH-4	NG\NcmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkGxTWM2OD13ND6xN\|gh\|ryP	MVjTRW5ITVJ?
NCI-H1693	M3\XVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTV2LkKxNFMh\|ryP	MkXjV2FPT0WU
BPH-1	NXfSZWxPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1ftO2lEPTB;NUWuNlg6OiEQvF2=	NIjFe4lUSU6JRWK=
CAMA-1	NWLsVJdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTV3LkixNVYh\|ryP	MWHTRW5ITVJ?
A388	M4OzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTV4LkC5PFUh\|ryP	NF\pPWxUSU6JRWK=
C2BBe1	NF\DR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPNbpBqUUN3ME21Ok4zPjN2IN88US=>	NX;VZ45IW0GQR1XS
GAMG	M{KyZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTV4LkW5OVUh\|ryP	M4PGRnNCVkeHUh?=
MKN28	NHPvSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vhR2lEPTB;NU[uPFAyOyEQvF2=	NYLIPVZVW0GQR1XS
VA-ES-BJ	NVHYNIVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DiPGlEPTB;NU[uPFc1PSEQvF2=	NX\j[3lXW0GQR1XS
HuCCT1	Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWq1NVdsUUN3ME21O{4xPDl{IN88US=>	MW\TRW5ITVJ?
BFTC-905	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3:wWGlEPTB;NUeuNlg6QCEQvF2=	MXHTRW5ITVJ?
LS-123	M2DpTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTV5LkW2Olgh\|ryP	M4q0OnNCVkeHUh?=
LB996-RCC	M2LXdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTV6LkCyPFch\|ryP	MYTTRW5ITVJ?
NCI-H1048	NFexTGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTV6LkKxPFgh\|ryP	NGr1O\|hUSU6JRWK=
COR-L105	NF7YZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DwNWlEPTB;NUiuO\|M{PyEQvF2=	NFy2RnBUSU6JRWK=
OVCAR-8	NG\zN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3T6TGlEPTB;NUmuNVcyPiEQvF2=	MVPTRW5ITVJ?
SK-N-FI	MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXNUoxKSzVyPUW5MlMzODdizszN	M4\iXXNCVkeHUh?=
MES-SA	NEOzZ\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\HfZFKSzVyPUW5MlQ2ODlizszN	MYrTRW5ITVJ?
SCC-9	NXHoZoFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPrXJVrUUN3ME21PU41PzV\|IN88US=>	NIX2bG1USU6JRWK=
EFO-27	Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTV7Lkm0N{DPxE1?	NXjaNnJMW0GQR1XS
GT3TKB	MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTZyLk[wOFgh\|ryP	MU\TRW5ITVJ?
HCC38	NVXENIlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkK1TWM2OD14MT60N\|c6KM7:TR?=	NWToeW1oW0GQR1XS
MLMA	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M132RmlEPTB;NkGuOlE3OyEQvF2=	MWXTRW5ITVJ?
D-566MG	NVyyTVlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIj5T3ZKSzVyPU[zMlUzOjRizszN	MVHTRW5ITVJ?
SF295	NHzTdGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTZ\|Lk[2OVUh\|ryP	MXnTRW5ITVJ?
ES4	M37nWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEewO\|NKSzVyPU[0MlQ4OTlizszN	MXjTRW5ITVJ?
CAKI-1	Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTZ2LkW3NlEh\|ryP	MoXSV2FPT0WU
OAW-28	NGH0ZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2THVWlEPTB;NkSuPVY1PyEQvF2=	NGj3UWRUSU6JRWK=
NCI-H460	M2C1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofUTWM2OD14NT6wPFk4KM7:TR?=	NF3CdJRUSU6JRWK=
JAR	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rw[mlEPTB;NkWuOVUyPiEQvF2=	MYnTRW5ITVJ?
SNU-449	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfuTWM2OD14NT63OlE3KM7:TR?=	NIDMcVlUSU6JRWK=
D-392MG	MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rJZWlEPTB;NkWuPVQ{PCEQvF2=	M2jleHNCVkeHUh?=
EW-22	NVXMW2dCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTZ4LkO5OUDPxE1?	MkLCV2FPT0WU
GCT	MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUD3eFZnUUN3ME22O{4xPDR\|IN88US=>	NVeycJo5W0GQR1XS
NOS-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLjTWM2OD14Nz62PFY4KM7:TR?=	MXTTRW5ITVJ?
RH-1	M2LtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTZ6LkW1OVkh\|ryP	M3i5bnNCVkeHUh?=
HuH-7	MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHxTWM2OD14OT6xNFAzKM7:TR?=	NW\ESpdiW0GQR1XS
NUGC-3	M2XVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnSzTWM2OD15MD65OlQ1KM7:TR?=	Mlz1V2FPT0WU
IST-SL1	MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHsXZdwUUN3ME23NU4zOzJ2IN88US=>	NFXtb41USU6JRWK=
SHP-77	M1Xte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXOe21EUUN3ME23Nk4yOTlizszN	MnXQV2FPT0WU
SW1116	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvGTWM2OD15Mj6xOFA4KM7:TR?=	MYTTRW5ITVJ?
LK-2	Mnr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HzSmlEPTB;N{KuPFYyOiEQvF2=	NVzjdZhPW0GQR1XS
U-2-OS	MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTd\|LkG4Nlgh\|ryP	M2rMfXNCVkeHUh?=
KYSE-150	NYjaRnVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTd\|Lk[xNVgh\|ryP	MkD1V2FPT0WU
U251	MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HxcWlEPTB;N{OuPFE3QCEQvF2=	Mn\lV2FPT0WU
HT-1080	NUjWTokxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjMXYpFUUN3ME23OE4zPTd2IN88US=>	NYrG[\|JnW0GQR1XS
NCI-H1437	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTd2Lk[zNlYh\|ryP	NVHvSYtMW0GQR1XS
HPAF-II	NV;odYxyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLJOWN{UUN3ME23OE43PDF3IN88US=>	MoXOV2FPT0WU
Becker	NYTa[GFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXuc2VKSzVyPUe1MlEyODVizszN	MWTTRW5ITVJ?
PANC-10-05	NW\FWHc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4j5OmlEPTB;N{WuNlg3PSEQvF2=	MUHTRW5ITVJ?
TYK-nu	NEn0PW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXoZXZ5UUN3ME23OU4{OTB{IN88US=>	NU\l[4Z1W0GQR1XS
SKG-IIIa	NFnWSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTKWGFKSzVyPUe1MlM{PDFizszN	NEPSNVRUSU6JRWK=
NCI-H1993	NGXmOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHjNIFKSzVyPUe1Mlc{QTdizszN	MWLTRW5ITVJ?
S-117	M1z2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvSXoVVUUN3ME23OU44PTVizszN	MYPTRW5ITVJ?
HuO9	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\OeoZKSzVyPUe2MlAxPDhizszN	MYHTRW5ITVJ?
CAL-51	Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPyZ4R4UUN3ME23Ok4yODB4IN88US=>	M{XIPHNCVkeHUh?=
BT-20	M37YPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17CZWlEPTB;N{[uNlE3QCEQvF2=	MoqzV2FPT0WU
LB831-BLC	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPKSFJKSzVyPUe2MlMzOTdizszN	MV\TRW5ITVJ?
LB1047-RCC	NEj3emZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTd4Lke2NVkh\|ryP	M2PFWHNCVkeHUh?=
ES8	M37qcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELs[mNKSzVyPUe4MlAxPzNizszN	NUP2Xpc2W0GQR1XS
UMC-11	Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2q4OWlEPTB;N{iuNFg5PCEQvF2=	NIXQbZBUSU6JRWK=
NCI-H226	NYLWfGlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTd6LkGzNVUh\|ryP	NUPleGJFW0GQR1XS
IGROV-1	M{C5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzCOmk3UUN3ME23PE42PTVizszN	NHyz[VBUSU6JRWK=
BHY	NWfjdlVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnRTnZKSzVyPUe5MlU6PiEQvF2=	NXu2[o1vW0GQR1XS
MKN45	M{XlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13NZWlEPTB;OECuN\|E4PCEQvF2=	MUXTRW5ITVJ?
IA-LM	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LocmlEPTB;OECuN\|UyOSEQvF2=	MYLTRW5ITVJ?
WM-115	MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\rPGlEPTB;OEGuOFEyPCEQvF2=	NGC0XJlUSU6JRWK=
VMRC-RCZ	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4W3SWlEPTB;OEGuOFQzPSEQvF2=	M17jd3NCVkeHUh?=
NCI-H2291	NFf1[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPYTWM2OD16MT62PFQzKM7:TR?=	MnXhV2FPT0WU
MCF7	Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVr6eHpvUUN3ME24N{4zQDl5IN88US=>	M{ntUXNCVkeHUh?=
639-V	NFXKXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX[4O41VUUN3ME24OE43OTJ7IN88US=>	MkXUV2FPT0WU
RT4	NFTwUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlGwTWM2OD16NT6yOFA{KM7:TR?=	NGPycWdUSU6JRWK=
NCI-H2405	Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3ldVhwUUN3ME24OU4zQTl5IN88US=>	MV;TRW5ITVJ?
CAL-33	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFq4eFFKSzVyPUi1MlY{OTVizszN	MX3TRW5ITVJ?
BT-549	NUPLTYpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rzXWlEPTB;OEWuPVM5OiEQvF2=	MXfTRW5ITVJ?
HT-1197	NY[4OpI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTh6LkGwO\|ch\|ryP	NWP1[WptW0GQR1XS
G-361	M1foc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTaTWM2OD16OD6xOFc1KM7:TR?=	M1LJb3NCVkeHUh?=
LS-411N	M1LRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrtTWM2OD16OT6zN\|g5KM7:TR?=	NF\ld\|JUSU6JRWK=
HT-144	NGrHdnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LzbWlEPTB;OEmuOVk6OiEQvF2=	M{\ncXNCVkeHUh?=
DJM-1	NXTye4tPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHrTWM2OD16OT64PFQ2KM7:TR?=	NWjYPYE4W0GQR1XS
CAL-12T	Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHPZpkzUUN3ME25NE44QDl3IN88US=>	Mn:0V2FPT0WU
MKN7	NW\hNolnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnruTWM2OD17MT6zOVUyKM7:TR?=	NIXMZnZUSU6JRWK=
HuP-T3	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTl4LkGwNFQh\|ryP	M4HYN3NCVkeHUh?=
SK-MG-1	MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkmwTWM2OD17Nj6xN\|Q5KM7:TR?=	NHHufXBUSU6JRWK=
NCI-H2347	NIDmO\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTl6LkGwOFIh\|ryP	NUXpeHJYW0GQR1XS
SW872	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonSTWM2OD1zMECuOFU3KM7:TR?=	MV3TRW5ITVJ?
COLO-829	M3\jZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTFyMD61OVMh\|ryP	M1PQcnNCVkeHUh?=
MC-IXC	MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzrUoo1UUN3ME2xNFAvPjF3IN88US=>	M2f1eHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Protocol

References

[1] Pearce LR, et al. Biochem J, 2010, 431(2), 245-255.

Solubility (25°C)

In vitro	DMSO	30 mg/mL (76.84 mM)
	Ethanol	8 mg/mL (20.49 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PF-4708671 SDF

Molecular Weight	390.41
Formula	C₁₉H₂₁F₃N₆
CAS No.	1255517-76-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products0

LY2584702 ^New

LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
LY2584702 Tosylate ^New

LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
BI-D1870

BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 HCl (CT99021) is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.
Everolimus (RAD001)

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

Choose Your Country or Region

By Signaling Pathways

By product type

PF-4708671